Syrebo

Syrebo operates at the intersection of neurorehabilitation, medical robotics, assistive technology and digital health. Its offering is broader than a single rehabilitation device: the portfolio includes soft hand-rehabilitation robots, upper-limb systems, lower-limb soft exoskeletons, electrical-stimulation equipment, gait-assistance products, mirror-therapy devices and assessment technologies using BCI, EMG and optical positioning. This combination gives the company exposure across hospitals, clinics and home-based care, while its stated FDA, CE and ISO 13485 credentials support sales in regulated markets. Syrebo’s stated reach of more than 4,000 hospitals and clinics and 60,000 households suggests meaningful deployment beyond an early laboratory stage. Its Series A financing also provides evidence of investor support for scaling this model.

Syrebo’s trajectory shows a progression from a 2017-founded rehabilitation-device developer to an internationally commercialized neurotechnology company. The first identifiable financing milestone was a Pre-Series A round in April 2021 stated at more than RMB 10 million. The next major inflection point came in March 2023, when the company raised nearly $15 million in a Series A led by 成都生物城股权投资基金. That financing appears to have supported expansion across a broad product family rather than a single application, including soft hand and lower-limb robotics, upper-limb rehabilitation, gait assistance, BCI and EMG interaction, flexible sensors and electrical stimulation. The growth case is constrained by limited disclosure: there is no employee-count trend, hiring detail, revenue history, valuation, later financing or dated product-launch record. Future momentum therefore depends on converting international deployment into recurring clinical and home-care adoption while maintaining regulatory and clinical credibility.